Literature DB >> 15516706

Unwelcome guests with master keys: how HIV enters cells and how it can be stopped.

Robert W Doms1.   

Abstract

HIV entry to host cells begins with binding of the viral envelope protein to CD4 molecules on the host cell surface. This binding initiates conformational changes in the envelope protein that result in binding to a coreceptor (CCR5 or CXCR4), exposure of a previously hidden domain in the viral protein, insertion of a viral fusion peptide into the host-cell membrane and fusing the viral and cell membranes. Each of these steps provides an opportunity for intervention to prevent viral entry, and a number of agents targeting these steps are in development. Studies of coreceptor inhibitors and fusion inhibitors have indicated the presence of host and viral factors that can result in variability of antiretroviral effect. Improved understanding of these factors will help to guide clinical use of these new agents. This article summarizes a presentation by Robert W. Doms, MD, PhD, at the International AIDS Society-USA course in Chicago in May 2004.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15516706

Source DB:  PubMed          Journal:  Top HIV Med        ISSN: 1542-8826


  9 in total

1.  The Ixodes scapularis salivary protein, salp15, prevents the association of HIV-1 gp120 and CD4.

Authors:  Ignacio J Juncadella; Renu Garg; Tonya C Bates; Elias R Olivera; Juan Anguita
Journal:  Biochem Biophys Res Commun       Date:  2007-12-26       Impact factor: 3.575

2.  Pilot study on the immunogenicity of paired Env immunogens from mother-to-child transmitted HIV-1 isolates.

Authors:  Shixia Wang; Michael Kishko; Shengqin Wan; Yan Wang; Frank Brewster; Glenda E Gray; Avye Violari; John L Sullivan; Mohan Somasundaran; Katherine Luzuriaga; Shan Lu
Journal:  Hum Vaccin Immunother       Date:  2012-11-01       Impact factor: 3.452

3.  HIV-1 tropism testing and clinical management of CCR5 antagonists: Quebec review and recommendations.

Authors:  Cécile Tremblay; Isabelle Hardy; Richard Lalonde; Benoit Trottier; Irina Tsarevsky; Louis-Philippe Vézina; Michel Roger; Mark Wainberg; Jean-Guy Baril
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

Review 4.  Current status and perspectives of plant-based candidate vaccines against the human immunodeficiency virus (HIV).

Authors:  Sergio Rosales-Mendoza; Néstor Rubio-Infante; Dania O Govea-Alonso; Leticia Moreno-Fierros
Journal:  Plant Cell Rep       Date:  2011-12-13       Impact factor: 4.570

5.  Epitope mapping of ibalizumab, a humanized anti-CD4 monoclonal antibody with anti-HIV-1 activity in infected patients.

Authors:  Ruijiang Song; David Franco; Chia-Ying Kao; Faye Yu; Yaoxing Huang; David D Ho
Journal:  J Virol       Date:  2010-05-12       Impact factor: 5.103

6.  Analysis of residues near the fusion peptide in the influenza hemagglutinin structure for roles in triggering membrane fusion.

Authors:  Sudha Thoennes; Zhu-Nan Li; Byeong-Jae Lee; William A Langley; John J Skehel; Rupert J Russell; David A Steinhauer
Journal:  Virology       Date:  2007-10-23       Impact factor: 3.616

7.  Genotypic and functional properties of early infant HIV-1 envelopes.

Authors:  Michael Kishko; Mohan Somasundaran; Frank Brewster; John L Sullivan; Paul R Clapham; Katherine Luzuriaga
Journal:  Retrovirology       Date:  2011-08-15       Impact factor: 4.602

8.  HIV-1 Fusion with CD4+ T cells Is Promoted by Proteins Involved in Endocytosis and Intracellular Membrane Trafficking.

Authors:  Mariana Marin; Yulia Kushnareva; Caleb S Mason; Sumit K Chanda; Gregory B Melikyan
Journal:  Viruses       Date:  2019-01-25       Impact factor: 5.048

9.  Stable gene transfer of CCR5 and CXCR4 siRNAs by sleeping beauty transposon system to confer HIV-1 resistance.

Authors:  Mayur Tamhane; Ramesh Akkina
Journal:  AIDS Res Ther       Date:  2008-07-30       Impact factor: 2.250

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.